454 related articles for article (PubMed ID: 25345511)
1. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
2. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
3. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
4. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
6. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
7. Phytochemical profiling and in vitro screening for anticholinesterase, antioxidant, antiglucosidase and neuroprotective effect of three traditional medicinal plants for Alzheimer's Disease and Diabetes Mellitus dual therapy.
Penumala M; Zinka RB; Shaik JB; Mallepalli SKR; Vadde R; Amooru DG
BMC Complement Altern Med; 2018 Mar; 18(1):77. PubMed ID: 29499679
[TBL] [Abstract][Full Text] [Related]
8. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
Macdonald IR; Rockwood K; Martin E; Darvesh S
J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
[TBL] [Abstract][Full Text] [Related]
10. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
11. Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.
Markowicz-Piasecka M; Sikora J; Mateusiak Ł; Mikiciuk-Olasik E; Huttunen KM
Oxid Med Cell Longev; 2017; 2017():7303096. PubMed ID: 28770024
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
13. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of antioxidant peptides obtained from enzymatic pea protein hydrolysates and their ultrafiltration peptide fractions.
Asen ND; Aluko RE
J Food Biochem; 2022 Nov; 46(11):e14289. PubMed ID: 35758753
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
18. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
19. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]